ST. LOUIS, Mo. Geneoscopy, Inc., a life sciences company specializing in gastrointestinal health diagnostics, has appointed Amit Bhalla as its new Chief Financial Officer (CFO). With over 25 years of experience in healthcare finance and strategy, Bhalla is set to play a key role in the company’s expansion and the commercial launch of its flagship colorectal cancer screening test, ColoSense®.
Geneoscopy CEO Andrew Barnell emphasized Bhalla’s financial expertise and deep industry knowledge as vital assets to the company’s growth. “Amit’s extensive financial leadership and understanding of the healthcare landscape will be invaluable as we scale operations and advance our mission of improving patient outcomes through innovative diagnostic solutions,” Barnell stated. “Following our recent $105 million Series C financing, his expertise will be instrumental in optimizing our financial strategy as we bring ColoSense to market and progress our pipeline of products for inflammatory bowel disease (IBD).”
Before joining Geneoscopy, Bhalla served as Executive Vice President and CFO at Sampled, a global biorepository and laboratory, where he oversaw financial, supply chain, and facilities operations. His previous roles include Vice President of Global Strategy & Development at Becton Dickinson and nearly two decades on Wall Street as a healthcare analyst and executive at firms such as Citi, Morgan Stanley, and Lord Abbett.
Bhalla expressed enthusiasm about his new role, stating, “This is an exciting time to join Geneoscopy’s leadership team, and I look forward to leveraging my background and experience to support its growth trajectory. With a strong financial foundation, a differentiated solution for colorectal cancer screening, and the resources to drive meaningful innovation, the company is well-positioned to transform gastrointestinal diagnostics, bringing life-changing solutions to more patients.”
Geneoscopy recently secured $105 million in Series C financing to support the commercial launch of ColoSense, which received FDA approval in May 2024. The funding will also accelerate the company’s efforts in precision medicine for IBD and further the development of its proprietary RNA technology platform.
